EUVIMEDEUVIMED entdecken
Crossref

PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification

Xiaoming Zhang, Aihui Wang, Lucy Han, Brooke Liang, Grace Allard, Elisabeth Diver, Brooke E Howitt

Modern Pathology · 2023

DOI: 10.1016/j.modpat.2023.100106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2023. Verfasst von Xiaoming Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stanford University School of Medicine, Stanford, California. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Carcinoma, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 84 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a critical tumor suppressor, PTEN has gained much attention in cancer research. Emerging evidence suggests an association between PTEN status and clinical outcome in certain tumors, and may be predictive of response to several therapies. However, the significance of PTEN deficiency in tubo-ovarian high-grade serous carcinomas (HGSCs) is still poorly understood. We evaluated PTEN expression in HGSCs and determined its clinical relevance. A cohort of 76 HGSC specimens was profiled using tissue microarray. Immunohistochemistry (IHC) of PTEN, ER, PR, AR, CD8, FOXP3, and PD-L1 was performed. Targeted gene panel testing by massively parallel sequencing was performed in 51 cases. PTEN deficiency (complete or subclonal loss) detected by IHC was identified in 13 of the 62 HGSCs (21%) and was significantly correlated with reduced expression of ER and worse first progression-free survival (P < .05) but not with PD-L1 expression, the density of intratumoral T lymphocytes, or overall survival. In our cohort, tumor progression within 1 year of PARP inhibitor therapy was found more frequently in PTEN-deficient cases than in PTEN-intact cases (100% vs 52%). Molecular profiling showed that intragenic mutation or deletion was not the predominant mechanism for PTEN inactivation in HGSCs. In addition, CCNE1 amplification was found to be mutually exclusive with PTEN deficiency at both protein and DNA levels. An analysis of the genomic data from 1702 HGSC samples deposited with The Cancer Genome Atlas database obtained from cBioPortal confirmed the low rate of detection of PTEN gene alterations and the mutually exclusive nature of PTEN loss and CCNE1 amplification in HGSCs. These findings indicate that PTEN deficiency defines a distinct clinically significant subgroup of HGSCs with a tendency for ER negativity, wild-type CCNE1 status, inferior clinical outcomes, and potential drug resistance. These tumors may benefit from PI3K pathway inhibitors in combination with other ovarian cancer regimens, which deserves further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsCarcinomaCystadenocarcinoma, SerousFemaleHumansProgression-Free SurvivalB7-H1 AntigenPhosphatidylinositol 3-KinasesOncogene ProteinsCyclin EPTEN Phosphohydrolase

Stichwörter der Autor:innen

CCNE1 amplificationPARP inhibitorPTEN deficiencyhigh-grade serous carcinomaimmunotherapy

Substanzen

B7-H1 AntigenPhosphatidylinositol 3-KinasesCCNE1 protein, humanOncogene ProteinsCyclin EPTEN protein, humanPTEN Phosphohydrolase

Autor:innen und Institutionen

  • Department of Pathology, Stanford University School of Medicine, Stanford, California.
  • Department of Pathology, Stanford University School of Medicine, Stanford, California; Department of Pathology, California Pacific Medical Center, San Francisco, California.
  • Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California; ImmunoGen, Inc, Waltham, Massachusetts.
  • Department of Pathology, Stanford University School of Medicine, Stanford, California. Electronic address: bhowitt@stanford.edu.

Zitieren

APA

Zhang, X., Wang, A., Han, L., Liang, B., Allard, G., Diver, E., & Howitt, B. E. (2023). PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification. Modern Pathology. https://doi.org/10.1016/j.modpat.2023.100106

Vancouver

Zhang X, Wang A, Han L, Liang B, Allard G, Diver E, et al. PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification. Modern Pathology. 2023. doi:10.1016/j.modpat.2023.100106

BibTeX
@article{Zhang2023,
  author = {Zhang, Xiaoming and Wang, Aihui and Han, Lucy and Liang, Brooke and Allard, Grace and Diver, Elisabeth and Howitt, Brooke E},
  title = {PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification},
  journal = {Modern Pathology},
  year = {2023},
  doi = {10.1016/j.modpat.2023.100106}
}
Kostenlos starten →